EP2655663A4 - Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease - Google Patents

Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Info

Publication number
EP2655663A4
EP2655663A4 EP11850360.6A EP11850360A EP2655663A4 EP 2655663 A4 EP2655663 A4 EP 2655663A4 EP 11850360 A EP11850360 A EP 11850360A EP 2655663 A4 EP2655663 A4 EP 2655663A4
Authority
EP
European Patent Office
Prior art keywords
colon cancer
cancer disease
side colon
biomarkers
prognosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11850360.6A
Other languages
German (de)
French (fr)
Other versions
EP2655663A2 (en
Inventor
Steven Buechler
Amanda B Hummon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Notre Dame
Original Assignee
University of Notre Dame
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Notre Dame filed Critical University of Notre Dame
Publication of EP2655663A2 publication Critical patent/EP2655663A2/en
Publication of EP2655663A4 publication Critical patent/EP2655663A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y106/00Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/03Oxidoreductases acting on NADH or NADPH (1.6) with oxygen as acceptor (1.6.3)
    • C12Y106/03001NAD(P)H oxidase (1.6.3.1), i.e. NOX1
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
EP11850360.6A 2010-12-20 2011-12-20 Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease Withdrawn EP2655663A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061459864P 2010-12-20 2010-12-20
PCT/US2011/066233 WO2012088146A2 (en) 2010-12-20 2011-12-20 Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Publications (2)

Publication Number Publication Date
EP2655663A2 EP2655663A2 (en) 2013-10-30
EP2655663A4 true EP2655663A4 (en) 2015-01-28

Family

ID=46314850

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11850360.6A Withdrawn EP2655663A4 (en) 2010-12-20 2011-12-20 Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Country Status (2)

Country Link
EP (1) EP2655663A4 (en)
WO (1) WO2012088146A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2821507A1 (en) * 2013-07-01 2015-01-07 Centre National de la Recherche Scientifique (CNRS) A method for detecting, identifying and/or quantifying a pathogen in an individual
CN114540499A (en) * 2022-03-17 2022-05-27 郑州源创吉因实业有限公司 Application of model constructed based on PCD related gene combination in preparation of product for predicting colon adenocarcinoma prognosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355149A2 (en) * 2002-03-29 2003-10-22 Ortho-Clinical Diagnostics, Inc. Assessing colorectal cancer
WO2005010486A2 (en) * 2003-07-18 2005-02-03 Lee Nancy M Biomarker panel for colorectal cancer
WO2010132817A1 (en) * 2009-05-14 2010-11-18 Cancer Prevention Pharmaceuticals, Llc Carcinoma diagnosis and treatments, based on odc1 genotype

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919061B1 (en) * 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DOSING PLASTINE-I FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355149A2 (en) * 2002-03-29 2003-10-22 Ortho-Clinical Diagnostics, Inc. Assessing colorectal cancer
WO2005010486A2 (en) * 2003-07-18 2005-02-03 Lee Nancy M Biomarker panel for colorectal cancer
WO2010132817A1 (en) * 2009-05-14 2010-11-18 Cancer Prevention Pharmaceuticals, Llc Carcinoma diagnosis and treatments, based on odc1 genotype

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012088146A2 *

Also Published As

Publication number Publication date
EP2655663A2 (en) 2013-10-30
WO2012088146A3 (en) 2012-10-11
WO2012088146A2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
SG10201710447QA (en) Pancreatic cancer biomarkers and uses thereof
IL223295A0 (en) Lung cancer biomarkers and uses thereof
IL222234A0 (en) Biomarkers for mdm2 inhibitors for use in treating disease
IL252163A0 (en) Lung cancer biomarkers and uses thereof
EP2382331A4 (en) Cancer biomarkers
EP2653546A4 (en) Marker for predicting stomach cancer prognosis and method for predicting stomach cancer prognosis
EP2536854A4 (en) Personalized tumor biomarkers
HK1175476A1 (en) Cancer treatment
GB0906458D0 (en) Macromolecules for diagnosis and prognosis
HK1206414A1 (en) Biomarkers for gastric cancer and uses thereof
GB0922085D0 (en) Cancer diagnosis and treatment
EP2457092A4 (en) Cancer biomarker and the use thereof
HK1143157A1 (en) 4-pyridinone compounds and their use for cancer 4-
IL222958A0 (en) Cancer treatment
HK1247207A1 (en) New compounds for treating cancer and other disease
EP2630498A4 (en) Prognostic biomarkers in patients with ovarian cancer
GB0901837D0 (en) Cancer diagnosis and treatment
EP2655663A4 (en) Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
EP2473613A4 (en) Cancer starvation therapy
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
EP2223117A4 (en) Breast cancer treatment and treatment prediction
TWI563256B (en) Marker for colon cancer and method for detecting colon cancer
EP2403963A4 (en) A biomarker and treatment for cancer
EP2612861A4 (en) Fluorinated thiazoles for use in treating cancer
EP2721410A4 (en) Biomarkers for epithelial cancer diagnosis and treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130722

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150107

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101ALI20141219BHEP

Ipc: C12N 15/113 20100101ALI20141219BHEP

Ipc: C12N 15/11 20060101ALI20141219BHEP

Ipc: C12Q 1/68 20060101AFI20141219BHEP

17Q First examination report despatched

Effective date: 20150915

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190103